Evasc Neurovascular has announced the successful use of the Eclips Short Landing Zone device in treating all anterior communicating artery (ACOM) and middle cerebral artery (MCA) bifurcation aneurysms. The first successful case using this pioneering device was performed by Jonas Jensen at Aarhus University Hospital in Aarhus, Denmark.
Alongside this clinical milestone, Evasc has also announced that the Eclips Short Landing Zone device has received CE-mark/Medical Device Regulation (MDR) approval. A company press release notes that this approval underscores the device’s safety and efficacy for use across the European Union.
Jensen performed the “groundbreaking” first procedure with Eclips, achieving “excellent results” and setting “a new standard” in the treatment of complex intracranial aneurysms, the release continues. The Eclips Short Landing Zone device—designed for stable aligning and orientation of the spine—offers a “paramount solution” for addressing bifurcation aneurysms in both ACOM and MCA regions. Its innovative design allows for enhanced navigation and deployment, thus ensuring optimal outcomes for patients, as per the release.
“We are extremely proud of this significant achievement,” said Wieger Kaptein, a representative of Evasc. “Now, we have an Eclips device for every bifurcation aneurysm, including BT [basilar tip], CT [carotid terminus], ACOM and MCA. We expect a potentially disruptive impact on the treatment of bifurcation aneurysms. The majority of all aneurysms are, after all, ACOM and MCA aneurysms.”
